Sebastian Guth, COO of Bayer Pharmaceuticals.Photo illustration: STAT; Photo: Bayer

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You can also read Sandoz CEO Richard Saynor on what the 2024 conversation is missing, Eli Lilly chief scientist Daniel M. Skovronsky on fallacies surrounding patents, drug discovery, and affordability, and Genentech executive Fritz Bittenbender on the danger of political soundbites.

The future of health care starts on Jan. 20, 2025. The stakes for Americans could not be higher.

Advertisement

Whether it’s Vice President Kamala Harris or former President Donald Trump in the White House that day, the health care industry must not lose sight of what matters most: giving all Americans more affordable access to the most innovative medicines.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe